Pfizer Withdraws Oxbryta: Implications for Sickle Cell Patients
Pfizer's Withdrawal of Oxbryta: Key Details
Pfizer is withdrawing all lots of Oxbryta (voxelotor) and discontinuing everything related to the drug, which is prescribed for patients with sickle cell disease. This significant choice comes after accumulating clinical data indicating an imbalance in vaso-occlusive crises and fatalities that require further scrutiny. Patients are urged to reach out to their healthcare providers to explore available alternative treatments.
Clinical Trials Discontinued
In light of the recent developments, Pfizer has suspended all clinical trials concerning Oxbryta while undertaking a comprehensive review of the available clinical data. Pfizer plans to update the public regarding the findings on this matter in future communications.
Company Background
Oxbryta was acquired by Pfizer during the purchase of Global Blood Therapeutics for approximately $5.4 billion in October 2022. In 2023 alone, this drug garnered sales of $328 million.
FDA Approval History
The FDA initially granted accelerated approval for Oxbryta in 2019 for treating sickle cell disease in individuals 12 years and older. This approval was later extended in December 2021 to include patients aged 4 and above.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.